Anticancer Drugs Course
Master first-line EGFR TKI strategies, manage toxicities, and navigate resistance in EGFR-mutant NSCLC. This Anticancer Drugs Course equips oncology professionals with practical tools to optimise patient outcomes and communicate effectively with patients, drawing on the latest evidence for confident decision-making in systemic treatments including targeted therapies, chemo-immunotherapy, and chemotherapy.

4 to 360 hours flexible workload
valid certificate in your country
What will I learn?
This course provides a focused overview of first-line systemic treatments for EGFR-mutated NSCLC, covering targeted therapies, chemo-immunotherapy, and chemotherapy. Participants will learn mechanisms of action, dosing schedules, toxicity profiles, prevention and management strategies, resistance mechanisms, second-line treatment options, monitoring protocols, and effective communication skills for evidence-based clinical decisions.
Elevify advantages
Develop skills
- EGFR TKI selection: choose first-line regimens using up-to-date trial evidence.
- Resistance workup: plan imaging, re-biopsy, and liquid biopsy to guide therapy.
- Second-line strategy: match resistance patterns to targeted, chemo, or trial options.
- Toxicity control: prevent and manage EGFR TKI rash, diarrhoea, ILD, and cytopenias.
- Patient counselling: explain goals, side effects, and progression plans in clear terms.
Suggested summary
Before starting, you can change the chapters and the workload. Choose which chapter to start with. Add or remove chapters. Increase or decrease the course workload.What our students say
FAQs
Who is Elevify? How does it work?
Do the courses have certificates?
Are the courses free?
What is the course duration?
What are the courses like?
How do the courses work?
What is the duration of the courses?
What is the cost or price of the courses?
What is an EAD or online course and how does it work?
PDF Course